Sengenics’ Immunome Protein Array Platform Has Five New Applications

Sengenics announced five new applications for its patented Immunome Protein Array platform, which has been used in recent studies to discover autoantibody biomarkers for many diseases including lupus. The news came during the Immunomics & Proteomics Symposium held July 25-29, in Brunei and Singapore.

Important presenters include world leaders in proteomics including Sengenics’ Chief Scientific Advisor and Immunome Technology Inventor Jonathan Blackburn; Roche’s Global Head of Proteomics in Switzerland, Hanno Langen; and theRoyal Institute of Technology’s Head of Atlas Protein Array group, in Sweden, Peter Nilsson.

“The ingenious surface technology of Immunome protein array makes it superior to those of its competitors, as it is able to identify biomarkers missed by other platforms and gives excellent signal-to-noise ratio. Every protein on the array is correctly folded and hence functional, making it ideal for a wide variety of proteomics applications, such as protein-protein and protein-DNA interaction profiling, on-array drug assays as well as monitoring adverse drug reactions in cancer immunotherapy clinical trials,” Blackburn said in a press release.

The Immunome protein array is the world’s first protein array platform where every protein is full-length, properly folded and functionally validated. Key applications of the technology include monitoring differential immune response to drugs and vaccines in clinical trials, and modeling viral or bacterial infection. Diagnostic biomarkers can be discovered for any disease that involves the immune system including autoimmune and neurodegenerative disorders and cancer.

“We are delighted and honored to co-host this landmark event with Sengenics that brings together distinguished international experts in proteomics to share their knowledge and expertise with the local community. We hope everyone who attends will benefit from this once-in-a-lifetime opportunity to interact and discuss their own research ideas with such an eminent field of experts,” said Dr. Joyce Teo Siew Yean, acting vice chancellor of  the Universiti Brunei Darussalam.

Sengenics’ partners have filed co-patents based on new biomarkers discovered using the Immunome. They plan to advance the biomarkers into clinical examinations to improve the precision of diagnosis and prognosis of diseases, patient stratification, and precision medicine in drug trials.